( NEW YORK--(BUSINESS WIRE)--Apr 10 2007...)Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting,Health

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. Additionally, preclinical data on INNO-206, a doxorubicin prodrug for the treatment of various cancers, will be presented. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to these presentations is as follows: -0-

Presentation Title:     "A phase I study of INNO-406, a dual inhibitor

                         of Abl/Lyn kinases, in adult patients with

                         imatinib-resistant or intolerant Philadelphia

                         chromosome positive (Ph+) leukemias"

----------------------- ----------------------------------------------

Abstract Number:        2637

----------------------- ----------------------------------------------

Session:                Poster Section 5, Clinical Research 11, Poster

                         Board #2

----------------------- ----------------------------------------------

Session Date and Time:  Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.

----------------------- ----------------------------------------------

Location:               Exhibit Hall, Los Angeles Convention Center

----------------------- ----------------------------------------------


----------------------- ----------------------------------------------

Presentation Title:     "Reduced chronic cardiotoxicity and

                         mitochondrial damage of the (6-

                         maleimidocaproyl) hydrazone derivative of

                         doxorubicin (DOXO-EMCH) in a rat model

                         compared to doxorubicin"

----------------------- ---------
'"/>




Page: 1 2 3 
Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study
of INNO-406 at the American Society of Clinical Oncology Annual
Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206
Oncology Program
3. Innovive Pharmaceuticals Announces Additional Data Presentations at
American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea